Quarterly report pursuant to Section 13 or 15(d)

Document and Entity Information

v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May 13, 2016
Document And Entity Information    
Entity Registrant Name GT Biopharma, Inc.  
Entity Central Index Key 0000109657  
Document Type 10-Q/A  
Document Period End Date Mar. 31, 2016  
Amendment Flag true  
Amendment Description

GT Biopharma, Inc., formerly known as Oxis International, Inc, (the “Company”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for its quarter ended March 31, 2016, as filed with the Securities and Exchange Commission on May 13, 2016 (the “Original March 2016 Form 10-Q”), primarily to correct an error related to the non-cash calculation of warranty liabilities.

 

Actual Changes in the Original March 2016 Form 10-Q. The actual changes in the Original March 2016 Form 10-Q included in this Amendment No. 1 are amendments to: (a) amended and restated Consolidated Statement of Operations for the three months ended March 31, 2016, (b) amended and restated Consolidated Statement of Cash Flows for the three months ended March 31, 2016, and (c) the addition of Note 7.

 

Notwithstanding that there are no changes in most of the Notes to the Consolidated Financial Statements included in this Amendment No. 1, a complete Form 10-Q document including a complete set of the Consolidated Financial Statements (together with all of the Notes from the Original March 2016 10-Q) has been included in this Amendment No. 1, for convenient reference.

 

In addition, see additional amended filings of the Company for relevant subsequent events.

 

 
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   22,431,221
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2016